Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis
{{output}}
Background & aims: Metabolic dysfunction-associated steatohepatitis (MASH), a progressive subtype of metabolic dysfunction-associated steatotic liver disease (MASLD), has limited pharmacological treatment options. Therefore, we a... ...
